← Leaderboards
George Miljanich
Siteone Therapeutics, Inc.
$601,209
Attributed
$1,202,418
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $681.1K · FY2013–14$1M$750K$500K$250K$0
'13
'14
Funding mix
By agency
NIH$1,202,418 · 3
By mechanism
R44$681,135 · 1
R43$521,283 · 2
Top collaborators
- John Vincent Mulcahy3 shared
Most similar at Siteone Therapeutics, Inc.
Same institution · by research overlap
- John Vincent Mulcahy$6,301,912
- Anton Delwig$2,325,019
- Debra Odink$3,260,885
- John Cureton Hunter$6,388,430
- Sheri Denet Klas$1,802,944
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainProtein IsoformsGuanidiniumMedicalPharmacological TreatmentPre-ClinicalDoseFamilyIntegral Membrane ProteinLeadPharmaceutical PreparationsAdverse EffectsAcutePositioning AttributeCellsCollectionDrug CandidateEvaluationHuman SubjectInhibitor/AntagonistIon ChannelCardiacAnalogPublic Health Relevance
Grant awards (3)
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$681,135
R44 · FY2014 · NS
Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord$285,048
R43 · FY2013 · GM
Design, Synthesis and Evaluation of Novel Isoform-Selective Sodium Channel Inhibi$236,235
R43 · FY2013 · NS